The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector. 

With positive results from a Phase II proof of concept controlled human infection model study evaluating Neumifil under its belt, the Scottish biotech is preparing to put the drug through its paces in a chronic obstructive pulmonary disease trial next year.

The French drugmaker is banking on the wealth of expertise that Houman Ashrafian brings as both a scientist and biotech entrepreneur to drive forward its R&D efforts.

Deal Snapshot: Gilead will collaborate with the start-up on the discovery and development of first-in-class targeted, multifunctional, conditional therapeutics.